Ablation Therapy with Radioiodine in Adults and Children with Differentiated Thyroid Cancer

  • Christoph  Reiners
  • Markus Dietlein
  • Frederik Verburg
  • Markus Luster
Part of the Medical Radiology book series (MEDRAD)


Ablation with radioiodine is an effective and low-risk-therapy modality in adults and children with differentiated thyroid cancer. According to international guidelines, radioiodine ablation is indicated in high risk patients (pT3, pT4, each N1, each M1) as well as in the low-risk group (pT1b, pT2) if the tumor is multifocal and if lymphnode metastases and/or distant metastases are present. Only in very low-risk patients with unifocal, papillary carcinomas ≤ 1 cm without unfavourable histological characteristics, radioiodine ablation is not necessary. Today, preparation with exogenous TSH-stimulation by injection of recombinant TSH (rhTSH) can be used as an alternative to endogenous TSH-stimulation in hypothyroidism. The activities of radioiodine needed for remnant ablation depend on the radicality of surgical thyroidectomy. The prognosis of patients with differentiated thyroid cancer after ablation therapy with radioiodine is generally excellent. But due to the very good prognosis, it is almost impossible to attain a sufficiently long-term follow-up for analysis of tumor specific mortality. However, it could be recently demonstrated, that a small but statistically significant reduction in the risk for developing distant metastases is related to thyroid remnant ablation by radioiodine. The biological behaviour of differentiated thyroid cancer in children is different, since 30-60 % of the patients present with tumor stages pT4 and 70–90 % with pN1 respectively. Nevertheless, treatment results are at least as good as in adults.


Thyroid Cancer Differentiate Thyroid Cancer Radioiodine Therapy Thyroid Remnant Urinary Iodine Excretion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM (1998) Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 39:1551–1554PubMedGoogle Scholar
  2. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Piazza F, Caciagli M, Mariani G (2003) Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88:4110–4115PubMedCrossRefGoogle Scholar
  3. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Turco A, Mariani G (2006) Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nucl Med Commun 27:627–632PubMedCrossRefGoogle Scholar
  4. Benua RS, Cicale NR, Sonenberg M, Rawson RW (1962) The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR 1962:171–182Google Scholar
  5. Bhattacharyya N, Chien W (2006) Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Ann Otol Rhinol Laryngol 115:607–610PubMedGoogle Scholar
  6. Bohrer T, Pasteur I, Lyutkevych O, Fleischmann P, Tronko M (2005) Permanent hypoparathyroidism due to thyroid cancer surgical procedures in patients exposed to radiation in the Chernobyl, Ukraine, nuclear reactor accident. Dtsch Med Wochenschr 130:2501–2506PubMedCrossRefGoogle Scholar
  7. Ceccarelli C, Battisti P, Gasperi M, Fantuzzi E, Pacini F, Gualdrini G, Pierantoni MC, Luciani A, Djokich D, Pinchera A (1999) Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer. J Nucl Med 40:1716–1721PubMedGoogle Scholar
  8. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214PubMedCrossRefGoogle Scholar
  9. Demidchik YE, Demidchik EP, Reiners C, Biko J, Mine M, Saenko VA, Yamashita S (2006) Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann Surg 243:525–532PubMedCentralPubMedCrossRefGoogle Scholar
  10. Dietlein M, Dressler J, Eschner W, Grunwald F, Lassmann M, Leisner B, Luster M, Moser E, Reiners C, Schicha H, Schober O (2007a) Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). Nuklearmedizin 46:213–219PubMedGoogle Scholar
  11. Dietlein M, Dressler J, Eschner W, Lassmann M, Leisner B, Reiners C, Schicha H (2007b) Procedure guideline for radioiodine test (version 3). Nuklearmedizin 46:198–202PubMedGoogle Scholar
  12. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L (1995) Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 36:21–27PubMedGoogle Scholar
  13. Duntas LH, Wartofsky L (2007) Cardiovascular risk and subclinical hypothyroidism: focus on lipids and new emerging risk factors. What is the evidence? Thyroid 17:1075–1084PubMedCrossRefGoogle Scholar
  14. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW (2009) Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 94:4171–4179PubMedCrossRefGoogle Scholar
  15. Flux GD, Haq M, Chittenden SJ, Buckley S, Hindorf C, Newbold K, Harmer CL (2010) A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 37:270–275PubMedCrossRefGoogle Scholar
  16. Freudenberg LS, Jentzen W, Görges R, Petrich T, Marlowe RJ, Knust J, Bockisch A (2007) 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin 46 121–128Google Scholar
  17. Grigsby PW, Gal-or A, Michalski JM, Doherty GM (2002) Childhood and adolescent thyroid carcinoma. Cancer 95:724–729PubMedCrossRefGoogle Scholar
  18. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA (2007) 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab 92:28–38PubMedCrossRefGoogle Scholar
  19. Handkiewicz-Junak D, Wloch J, Roskosz J, Krajewska J, Kropinska A, Pomorski L, Kukulska A, Prokurat A, Wygoda Z, Jarzab B (2007) Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med 48:879–888PubMedCrossRefGoogle Scholar
  20. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C (2006) Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:654Google Scholar
  21. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR (2002) Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26:879–885PubMedCrossRefGoogle Scholar
  22. Hoe FM, Charron M, Moshang T Jr (2006) Use of the recombinant human TSH stimulated thyroglobulin level and diagnostic whole body scan in children with differentiated thyroid carcinoma. J Pediatr Endocrinol Metab 19:25–30PubMedCrossRefGoogle Scholar
  23. Iorcansky S, Herzovich V, Qualey RR, Tuttle RM (2005) Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer. J Clin Endocrinol Metab 90:6553–6555PubMedCrossRefGoogle Scholar
  24. Jarzab B, Handkiewicz JD, Wloch J, Kalemba B, Roskosz J, Kukulska A, Puch Z (2000) Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. Eur J Nucl Med 27:833–841PubMedCrossRefGoogle Scholar
  25. Jarzab B, Handkiewicz-Junak D, Wloch J (2005) Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer 12:773–803PubMedCrossRefGoogle Scholar
  26. Kohlfuerst S, Igerc I, Lobnig M, Gallowitsch HJ, Gomez-Segovia I, Matschnig S, Mayr J, Mikosch P, Beheshti M, Lind P (2009) Posttherapeutic (131)I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. Eur J Nucl Med Mol Imaging 36:886–893PubMedCrossRefGoogle Scholar
  27. Krassas GE, Pontikides N (2005) Gonadal effect of radiation from 131I in male patients with thyroid carcinoma. Arch Androl 51:171–175PubMedCrossRefGoogle Scholar
  28. Kuijt WJ, Huang SA (2005) Children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia within 14 days of levothyroxine withdrawal. J Clin Endocrinol Metab 90:6123–6125PubMedCrossRefGoogle Scholar
  29. La Quaglia MP, Corbally MT, Heller G, Exelby PR, Brennan MF (1988) Recurrence and morbidity in differentiated thyroid carcinoma in children. Surgery 104:1149–1156PubMedGoogle Scholar
  30. La Quaglia MP, Black T, Holcomb GW III, Sklar C, Azizkhan RG, Haase GM, Newman KD (2000) Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children’s Cancer Group. J Pediatr Surg 35:955–959PubMedCrossRefGoogle Scholar
  31. Lassmann M, Luster M, Hanscheid H, Reiners C (2004) Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 45:619–625PubMedGoogle Scholar
  32. Lassmann M, Haenscheid H, Chiesa C, Hindorf C, Flux G, Luster M (2008) EANM dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 35:1405–1412PubMedCrossRefGoogle Scholar
  33. Lau WF, Zacharin MR, Waters K, Wheeler G, Johnston V, Hicks RJ (2006) Management of paediatric thyroid carcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy. Intern Med J 36:564–570PubMedCrossRefGoogle Scholar
  34. Loffler M, Weckesser M, Franzius C, Kies P, Schober O (2003) Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma. Nuklearmedizin 42:240–243PubMedGoogle Scholar
  35. Lundh C, Norden MM, Nilsson M, Forssell-Aronsson E (2007) Reduced iodide transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro. J Nucl Med 48:481–486PubMedGoogle Scholar
  36. Lundh C, Lindencrona U, Postgard P, Carlsson T, Nilsson M, Forssell-Aronsson E (2009) Radiation-induced thyroid stunning: differential effects of (123)I, (131)I, (99 m)Tc, and (211)At on iodide transport and NIS mRNA expression in cultured thyroid cells. J Nucl Med 50:1161–1167PubMedCrossRefGoogle Scholar
  37. Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hanscheid H, Reiners C (2003) Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 30:1371–1377PubMedCrossRefGoogle Scholar
  38. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F (2005) rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 12:49–64PubMedCrossRefGoogle Scholar
  39. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E (2008) Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35:1941–1959PubMedCrossRefGoogle Scholar
  40. Luster M, Handkiewicz-Junak D, Grossi A, Zacharin M, Taieb D, Cruz O, Hitzel A, Casas JA, Mader U, Dottorini ME (2009) Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study. J Clin Endocrinol Metab 94:3948–3953PubMedCrossRefGoogle Scholar
  41. Machens A, Holzhusen HJ, Dralle H (2005) The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. A comparative analysis. Cancer 103:2269–2273Google Scholar
  42. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL (1983) Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309:937–941PubMedCrossRefGoogle Scholar
  43. Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428PubMedCrossRefGoogle Scholar
  44. Medvedec M (2005) Thyroid stunning in vivo and in vitro. Nucl Med Commun 26:731–735PubMedCrossRefGoogle Scholar
  45. Mernagh P, Campbell S, Dietlein M, Luster M, Mazzaferri E, Weston AR (2006) Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 155:405–414PubMedCrossRefGoogle Scholar
  46. Newman KD, Black T, Heller G, Azizkhan RG, Holcomb GW III, Sklar C, Vlamis V, Haase GM, La Quaglia MP (1998) Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children’s Cancer Group. Ann Surg 227:533–541PubMedCentralPubMedCrossRefGoogle Scholar
  47. Oliynyk V, Epshtein O, Sovenko T, Tronko M, Elisei R, Pacini F, Pinchera A (2001) Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer. J Endocrinol Invest 24:445–447PubMedCrossRefGoogle Scholar
  48. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A (2002) Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87:4063–4068PubMedCrossRefGoogle Scholar
  49. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Reiners C, Sanchez FF, Smit J, Wiersinga W (2005) Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 153:651–659PubMedCrossRefGoogle Scholar
  50. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C (2006a) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926–932PubMedCrossRefGoogle Scholar
  51. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C (2006b) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926–932PubMedCrossRefGoogle Scholar
  52. Pacini F, Castagna MG, Brilli L, Pentheroudakis G (2010) Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v214–v219PubMedCrossRefGoogle Scholar
  53. Park EK, Chung JK, Lim IH, Park dJ, Lee DS, Lee MC, Cho BY (2009) Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging 36:172–179PubMedCrossRefGoogle Scholar
  54. Pelizzo MR, Boschin IM, Toniato A, Pagetta C, Piotto A, Bernante P, Casara D, Pennelli G, Rubello D (2004) Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nucl Med Commun 25:547–552PubMedCrossRefGoogle Scholar
  55. Pilli T, Brianzoni E, Capocetti F, Castagna MG, Fattori S, Poggiu A, Rossi G, Ferretti F, Guarino E, Burroni L, Vattimo A, Cipri C, Pacini F (2007) A comparison of 1850 (50 mCi) and 3700 (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542–3546PubMedCrossRefGoogle Scholar
  56. Rahbar K, Hutzenlaub V, Fischer RJ, Schober O, Riemann B (2008) Risk-profile and outcome of small papillary and follicular thyroid carcinomas (<1 cm). Nuklearmedizin 47:188–193PubMedGoogle Scholar
  57. Ralli M, Cohan P, Lee K (2005) Successful use of recombinant human thyrotropin in the therapy of pediatric well-differentiated thyroid cancer. J Endocrinol Invest 28:270–273PubMedCrossRefGoogle Scholar
  58. Reiners C, Dietlein M, Luster M (2008a) Radio-iodine therapy in differentiated thyroid cancer: indications and procedures. Best Pract Res Clin Endocrinol Metab 22:989–1007PubMedCrossRefGoogle Scholar
  59. Reiners C, Demidchik YE, Drozd VM, Biko J (2008b) Thyroid cancer in infants and adolescents after Chernobyl. Minerva Endocrinol 33:381–395PubMedGoogle Scholar
  60. Rivkees SA, Mazzaferri LA, Verburg FA, Reiners C, Luster M, Breuer CK, Dinauer CA, Udelsman R (2011) The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy. Endocr Rev 32:798–826PubMedCentralPubMedCrossRefGoogle Scholar
  61. Rubino C, De Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M (2003) Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638–1644PubMedCentralPubMedCrossRefGoogle Scholar
  62. Rybakov SJ, Komissarenko IV, Tronko ND, Kvachenyuk AN, Bodganova TI, Kovalenko AE, Bolgov MY (2000) Thyroid cancer in children of ukraine after the Chernobyl accident. World J Surg 24:1446–1449PubMedCrossRefGoogle Scholar
  63. Salvatori M, Luster M (2010) Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 37:821–828PubMedCrossRefGoogle Scholar
  64. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC (2004) Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668–3676PubMedCrossRefGoogle Scholar
  65. Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, Straus S, Goldstein DP (2008a) An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 37:457–480PubMedCrossRefGoogle Scholar
  66. Sawka AM, Goldstein DP, Thabane L, Brierley JD, Tsang RW, Rotstein L, Kamalanathan S, Zhao B, Gafni A, Straus S, Ezzat S (2008b) Basis for physician recommendations for adjuvant radioiodine therapy in early-stage thyroid carcinoma: principal findings of the Canadian-American thyroid cancer survey. Endocr Pract 14:175–184PubMedCrossRefGoogle Scholar
  67. Schlumberger M, De Vathaire F, Travagli JP, Vassal G, Lemerle J, Parmentier C, Tubiana M (1987a) Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab 65:1088–1094PubMedCrossRefGoogle Scholar
  68. Schlumberger M, Travagli JP, Lemerle J, Parmentier C (1987b) Differentiated thyroid carcinoma in childhood. Experience at Institut Gustave-Roussy, Villejuif. Acta Otorhinolaryngol Belg 41:804–808PubMedGoogle Scholar
  69. Schlumberger M, De Vathaire F, Ceccarelli C, Delisle MJ, Francese C, Couette JE, Pinchera A, Parmentier C (1996) Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 37:606–612PubMedGoogle Scholar
  70. Schmidt D, Szikszai A, Linke R, Bautz W, Kuwert T (2009) Impact of 131I SPECT/Spiral CT on nodal staging of differentiated thyroid carcinoma at first radioablation. J Nucl Med 50:18–23PubMedCrossRefGoogle Scholar
  71. Segal K, Shvero J, Stern Y, Mechlis S, Feinmesser R (1998) Surgery of thyroid cancer in children and adolescents. Head Neck 20:293–297PubMedCrossRefGoogle Scholar
  72. Serhal DI, Nasrallah MP, Arafah BM (2004) Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer. J Clin Endocrinol Metab 89:3285–3289PubMedCrossRefGoogle Scholar
  73. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, New-YorkGoogle Scholar
  74. Tala Jury HP, Castagna MG, Fioravanti C, Cipri C, Brianzoni E, Pacini F (2010) Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metab 95:230–237Google Scholar
  75. Thompson GB, Hay ID (2004) Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma. World J Surg 28:1187–1198PubMedCrossRefGoogle Scholar
  76. Tronko MD, Bogdanova TI, Komissarenko IV, Epstein OV, Oliynyk V, Kovalenko A, Likhtarev IA, Kairo I, Peters SB, LiVolsi VA (1999) Thyroid carcinoma in children and adolescents in Ukraine after the Chernobyl nuclear accident: statistical data and clinicomorphologic characteristics. Cancer 86:149–156PubMedCrossRefGoogle Scholar
  77. Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, Fleisher M, Robbins RJ (2008a) Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 49:764–770PubMedCrossRefGoogle Scholar
  78. Tuttle RM, Leboeuf R, Shaha AR (2008b) Medical Management of thyroid cancer: a risk adapted approach. J Surg Oncol 97:712–716PubMedCrossRefGoogle Scholar
  79. Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Grewal R, Brokhin M, Omry G, Larson S (2010) Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid 20:257–263PubMedCrossRefGoogle Scholar
  80. van Santen HM, Aronson DC, Vulsma T, Tummers RF, Geenen MM, de Vijlder JJ (2004) van den BC. Frequent adverse events after treatment for childhood-onset differentiated thyroid carcinoma: a single institute experience. Eur J Cancer 40:1743–1751PubMedCrossRefGoogle Scholar
  81. Vassilopoulou-Sellin R, Goepfert H, Raney B, Schultz PN (1998) Differentiated thyroid cancer in children and adolescents: clinical outcome and mortality after long-term follow-up. Head Neck 20:549–555PubMedCrossRefGoogle Scholar
  82. Verburg FA, de Keizer B, Lips CJ, Zelissen PM, de Klerk JM (2005) Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol 152:33–37PubMedCrossRefGoogle Scholar
  83. Verburg FA, Mader U, Luster M, Reiners C (2008) Primary tumor diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 71:291–297CrossRefGoogle Scholar
  84. Verburg FA, Verkooijen R, Stokkel M, van Isselt J (2009) The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I. Nuklearmedizin 48:138–142PubMedGoogle Scholar
  85. Verburg FA, Hanscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC, Reiners C, Luster M (2010a) Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging 37:896–903PubMedCrossRefGoogle Scholar
  86. Verburg FA, Stokkel MP, Duren C, Verkooijen RB, Mader U, van Isselt JW, Marlowe RJ, Smit JW, Reiners C, Luster M (2010b) No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 37:276–283PubMedCrossRefGoogle Scholar
  87. Zimmerman D, Hay ID, Gough IR, Goellner JR, Ryan JJ, Grant CS, McConahey WM (1988) Papillary thyroid carcinoma in children and adults: long-term follow-up of 1039 patients conservatively treated at one institution during three decades. Surgery 104:1157–1166PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg  2012

Authors and Affiliations

  • Christoph  Reiners
    • 1
  • Markus Dietlein
    • 2
  • Frederik Verburg
    • 3
  • Markus Luster
    • 4
  1. 1.Department of Nuclear MedicineUniversity Hospital, University of WuerzburgWuerzburgGermany
  2. 2.Department of Nuclear MedicineUniversity Hospital, University of CologneKölinGermany
  3. 3.Department of Nuclear MedicineUniversity Hospital, University of AachenAachenGermany
  4. 4.Department of Nuclear MedicineUniversity Hospital, University of UlmUlmGermany

Personalised recommendations